Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Promising Early Results with Immunotherapy for Mesothelioma
gracevideo
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
[powerpress]
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our Discussion Forums.
Transcript
Dr. West: Turning to the issues of what’s emerging in mesothelioma, it seems that there’s a lot of interest in immunotherapies in this setting. Any sense of early data in that, how hopeful you are?
Dr. Solomon: So, it was with pembrolizumab, and again, a small study, and a response rate of about 29%, and I think that’s encouraging, and I think this is in patients who had prior platinum pemetrexed, and this is a setting where there isn’t a standard second-line treatment, so I think that sort of response rate, again, is a meaningful response rate, and there are a number of other studies that are going with the other different PD-1 or PD-L1 inhibitors, alone or in combination with CTLA-4 inhibitors.
Dr. Horn: The pembrolizumab study, from what I remember, was only in PD-L1-positive patients.
Dr. Solomon: I think that’s right, and we may talk about PD-L1 as a biomarker later, but I think an interesting observation was that the didn’t find that the degree of PD-L1 scoring correlated with the likelihood of response, in mesothelioma.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Recent Comments
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: